Compare SYPR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYPR | ACRV |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.5M | 82.2M |
| IPO Year | 1996 | 2022 |
| Metric | SYPR | ACRV |
|---|---|---|
| Price | $2.91 | $1.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 69.0K | ★ 506.2K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,294,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.79 | $1.05 |
| 52 Week High | $4.74 | $3.56 |
| Indicator | SYPR | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 46.66 |
| Support Level | $1.98 | $1.73 |
| Resistance Level | $3.58 | $1.86 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 28.70 | 25.38 |
Sypris Solutions Inc provides products and engineering, design, and manufacturing services for a variety of critical infrastructure sectors, including energy, space, communications, defense, transport, chemical, and water. The company operates in two segments, Sypris Technologies and Sypris Electronics. Sypris Technologies segment includes the sale of forged, machined, welded and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications, whereas the Sypris Electronics segment includes revenue from circuit card and box build manufacturing, high reliability manufacturing and systems assembly and integration, for aerospace and defense, communications and space applications. The majority of revenue is derived from the Sypris Electronics segment.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.